PMID- 21155707
OWN - NLM
STAT- MEDLINE
DCOM- 20110512
LR  - 20141120
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 27
IP  - 2
DP  - 2011 Feb
TI  - Utilisation, efficacy and safety of voriconazole: prospective, non-interventional 
      study on treatment of IFIs in clinical practice.
PG  - 335-42
LID - 10.1185/03007995.2010.542137 [doi]
AB  - OBJECTIVE: Invasive fungal infections (IFIs) are an important cause of morbidity 
      and mortality, particularly in patients with cancer. The triazole voriconazole, 
      given as oral or intravenous formulation, has a high bioavailability and proven 
      efficacy against invasive aspergillosis, candidiasis and other fungi. We aimed to 
      assess the utilisation, efficacy and safety of voriconazole with emphasis on the 
      route of administration under standard clinical conditions. METHODS: Prospective, 
      observational study performed by 17 hospitals and office-based physicians in 
      Germany. RESULTS: A total of 264 patients received oral (53%) or intravenous 
      (22%) voriconazole or both formulations sequentially (25%). Of 228 patients with 
      specified fungal diagnosis, 95 (36.0%) had aspergillosis, 73 (27.7%) candidiasis. 
      Sixty (22.7%) received voriconazole for other fungal indications (OFI). In 195 of 
      226 patients (86.2%), treatment was successful (39.8% cured and 46.5% partial 
      response). In terms of primary diagnoses, favourable responses were noted in 90% 
      for pulmonary aspergillosis, 85% for candidiasis and 87% for OFI. Microbiological 
      success was documented in 138 patients, of whom 105 (76.1%) had complete 
      eradication of fungi. Response rates by initial route were similar for oral and 
      intravenous administration (86 and 87%). Twenty-six of 264 patients died during 
      the study, 53 patients experienced a serious adverse event (five treatment 
      related), and 10 withdrew due to all-causality adverse events (AEs). Tolerability 
      was assessed as very good in 55%, and good in 40% of patients. CONCLUSIONS: 
      Voriconazole as oral or intravenous formulation was well tolerated and equally 
      effective in critically ill patients with IFIs. This study in daily care confirms 
      the outcomes of controlled clinical trials.
FAU - Heinz, Werner J
AU  - Heinz WJ
AD  - Department of Internal Medicine II, Division of Infectious Diseases, University 
      of Wuerzburg Medical Centre, Wuerzburg, Germany. Heinz_w@klinik.uni-wuerzburg.de
FAU - Silling, Gerda
AU  - Silling G
FAU - Bohme, Angelika
AU  - Bohme A
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20101215
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Antifungal Agents)
RN  - 0 (Pyrimidines)
RN  - 0 (Triazoles)
RN  - JFU09I87TR (Voriconazole)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antifungal Agents/administration & dosage/adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Critical Illness/epidemiology/therapy
MH  - Female
MH  - Humans
MH  - Infant
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Mycoses/*drug therapy/epidemiology
MH  - Professional Practice/*statistics & numerical data
MH  - Prospective Studies
MH  - Pyrimidines/*administration & dosage/*adverse effects
MH  - Treatment Outcome
MH  - Triazoles/*administration & dosage/*adverse effects
MH  - Voriconazole
MH  - Young Adult
EDAT- 2010/12/16 06:00
MHDA- 2011/05/13 06:00
CRDT- 2010/12/16 06:00
PHST- 2010/12/16 06:00 [entrez]
PHST- 2010/12/16 06:00 [pubmed]
PHST- 2011/05/13 06:00 [medline]
AID - 10.1185/03007995.2010.542137 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2011 Feb;27(2):335-42. doi: 10.1185/03007995.2010.542137. Epub 
      2010 Dec 15.